155 reports of this reaction
2.3% of all CALCIUM POLYCARBOPHIL reports
#7 most reported adverse reaction
DYSPNOEA is the #7 most commonly reported adverse reaction for CALCIUM POLYCARBOPHIL, manufactured by Aurobindo Pharma Limited. There are 155 FDA adverse event reports linking CALCIUM POLYCARBOPHIL to DYSPNOEA. This represents approximately 2.3% of all 6,699 adverse event reports for this drug.
Patients taking CALCIUM POLYCARBOPHIL who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for CALCIUM POLYCARBOPHIL, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for CALCIUM POLYCARBOPHIL:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 155 FDA reports for CALCIUM POLYCARBOPHIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.3% of all adverse event reports for CALCIUM POLYCARBOPHIL, making it a notable side effect.
If you experience dyspnoea while taking CALCIUM POLYCARBOPHIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.